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Abstract
Background: Simian Virus 40 (SV40) immortalization followed by treatment of cells with 3-methylcholanthrene
(3-MC) has been used to elicit tumors in athymic mice. 3-MC carcinogenesis has been thoroughly studied, however
gene-level interactions between 3-MC and SV40 that could have produced the observed tumors have not been
explored. The commercially-available human uroepithelial cell lines were either SV40-immortalized (HUC) or
SV40-immortalized and then 3-MC-transformed (HUC-TC).
Results: To characterize the SV40 - 3MC interaction, we compared human gene expression in these cell lines using
a human cancer array and confirmed selected changes by RT-PCR. Many viral Large T Antigen (Tag) expression-
related changes occurred in HUC-TC, and it is concluded that SV40 and 3-MC may act synergistically to transform
cells. Changes noted in IFP 9-27, 2’-5’ OAS, IF 56, MxA and MxAB were typical of those that occur in response to viral
exposure and are part of the innate immune response. Because interferon is crucial to innate immune host
defenses and many gene changes were interferon-related, we explored cellular growth responses to exogenous
IFN-g and found that treatment impeded growth in tumor, but not immortalized HUC on days 4 - 7. Cellular
metabolism however, was inhibited in both cell types. We conclude that IFN-g metabolic responses were functional
in both cell lines, but IFN-g anti-proliferative responses functioned only in tumor cells.
Conclusions: Synergism of SV40 with 3-MC or other environmental carcinogens may be of concern as SV40 is
now endemic in 2-5.9% of the U.S. population. In addition, SV40-immortalization is a generally-accepted method
used in many research materials, but the possibility of off-target effects in studies carried out using these cells has
not been considered. We hope that our work will stimulate further study of this important phenomenon.
Background
Simian virus 40 (SV40) was first recognized and isolated
during the late 1950’s [1] and recently achieved fame
because it was carried over inadvertently as live virus
into poliovirus vaccine preparations from 1955-1963 in
the U.S. and elsewhere [2]. Approximately 60% of the
population in the U.S. and abroad was exposed to SV40.
Initially this caused little alarm, but the virus was later
found to induce mesotheliomas in hamsters [3,4] and
afterwards was found in a high percentage of certain
types of human cancers, especially mesotheliomas, but
not in surrounding tissues [reviewed in [2]]. Discussions
and investigations regarding the molecular identity of
the SV40 isolates, revealed the sequences found in can-
cers were ‘wild type’, not laboratory strains [5], ruling
out artifacts. Retrospective studies on human cohorts
inadvertently exposed to SV40 via poliovirus vaccine
increased the level of concern. A two-fold elevation in
the risk of neural cancers was noted in the children of
50,000 individuals exposed to SV40 during pregnancy
[5], though study design criticisms were registered. A
three-fold elevation in the incidence of mesothelioma
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cohort [2], and other studies reviewed therein also indi-
cated an elevated risk of brain tumors. SV40 seropreva-
lence in children born in Texas from 1980-95 indicates
that endemic levels of infection are 5.9% [6], or, as
reviewed in Butel and Lednicky, from 3 to 13% of the
number of persons not exposed to vaccine [5]. A recent
investigation points to an actual prevalence of 2% [7]
after correcting for cross-reactivity to JC and BK viruses.
In Finland, where SV40 was not a contaminant in polio-
virus vaccine, the seroprevalence is zero. A vaccine
against SV40 [8] is being developed.
There is a wealth of information about the mechan-
isms of action of SV40 in rodent and human cells in
vitro and in vivo [9-13]. SV40 Tag was found to bind
and inactivate p53 and pRB, abrogating apoptotic
mechanisms and control of cell proliferation, allowing
cellular overgrowth and escape from senescence, and
interestingly Tag-p53 complexes bind and activate the
IGF-1 promoter, resulting in increased malignant cell
growth [14,15]. Tag also binds the co-activators of IRF
transcription, p300 and CBP [12]. Small t antigen (tag)
immortalizes cells in conjunction with Tag [9], through
binding and inhibition of protein phosphatase 2A. Infor-
mation concerning the permissivity of human cells for
SV40 has emerged [6,16] whereby p53 binding to Tag
partially inactivated viral replicase activity, and then
cells could support an active (but low-level) infection
without a lytic component, together with a level of Tag
presence which failed to activate a full-blown immune
response [6]. Episomal and DNA-integrated viral repli-
cation are possible during such infection. For a more
recent and extremely thorough treatment of SV40 infec-
tion, latency, and transformation of human mesothelial
cells, see [17]. Testa et al. [10] suggest that asbestos and
SV40 are co-carcinogenic, which may contribute to the
long latency period between asbestos exposure and the
development of mesothelioma (which is most often
associated with the presence of SV40 virus in humans,
and also with asbestos exposure). Definitive recent work
by Kroczynska, et al. [18] demonstrated that crocidolite
asbestos and SV40 are co-carcinogens in human
mesothelial cells, and in causing mesothelioma in ham-
sters. In that study, SV40 did not cause malignant
mesothelioma per se, but increased the incidence from
20% (crocidolite alone) to 90% (crocidolite + SV40).
3-MC is a well-known, thoroughly investigated, potent
human and animal hepatocarcinogen of the type known
as polycyclic aromatic hydrocarbons (PAH), which bind
to the cytosolic Ah receptor, translocate to the nucleus
via association with ARNT, and in association with
ARNT bind DNA, activating transcription of genes con-
taining XRE’s or ARE’s [19] (such as CYP1A1)a n de l i -
citing an AP-1 antioxidant response. The gene
expression of 3-MC has been investigated in exposed rat
kidney/liver, and mouse liver [20-22] and in vitro in rat
hepatocytes [23], and compared to other hepatotoxi-
cants. Gene expression changes included the induction
of GSTμ,C Y P 1 A 1and A2, and several acute phase pro-
teins in the liver, and CYP1A1 and A2 in the kidney
[21]. PAH also form direct protein-DNA adducts [19].
However, the gene expression patterns induced by 3-
MC in conjunction with SV40 used as an immortalizing
principle have not been described. Human uroepithelial
cells immortalized with SV40 (hereafter referred to as
HUC) were compared to the descendant MC-SV-HUC-
T-2 (hereafter referred to as HUC-TC) line which was
immortalized by SV40 and subsequently transformed to
tumorigenicity using 3-MC, in order to observe specific
gene expression changes induced by the transforming
agent. Previously, Reznikoff et al. [24] developed these
cell lines and showed that treatment of HUC with SV40
followed by 3-MC, but not with either treatment indivi-
dually, produced tumors in athymic mice. In the present
experiment, we expected to see up-regulation of onco-
genes, down-regulation of tumor suppressor genes, and
other evidence of activation typical of cancer cell lines.
In actuality, many were clearly virally-related when com-
pared to the already virally-immortalized HUC, indicat-
ing a possible new interactionb e t w e e nv i r a le l e m e n t s
and 3-MC during cellular transformation to full tumori-
genicity. Here we explore those changes and discuss
their possible biological significance.
Results
Cell Morphology and Histologic Staining
In order to visually corroborate whether there was evi-
dence for increased proliferation or apoptosis in either
cell line, and to confirm whether HUC-TC had a more,
or a less abnormal appearance than HUC (as evidenced
by such criteria as heterogeneity of size or multiple/dis-
torted nuclei) we examined HUC and HUC-TC using
light microscopy. We also wished to observe first-hand
whether vacuolation due to SV40 infection was present
in either or both of the cell lines. We measured the pro-
liferation of both cell lines in order to determine if a
growth advantage occurred by 3-MC transformation.
Untransformed, immortalized HUC appeared generally
epithelioid (Fig. 1a) being rounded with faintly eosinophi-
lic cytoplasmic staining and darker pink stippled nuclear
staining. Occasionally cells displayed grossly increased
cytoplasmic to nuclear ratio and numerous mitotic fig-
ures were visible. In Fig. 1b, darker staining rounded cells
represent cells with condensed chromatin in prophase of
the cell cycle. The cells were not contact inhibited and
piled into layers and dense foci if not passaged.
HUC-TC cells (Fig. 1b) also appeared epithelioid and
displayed frequent mitotic figures, but were larger than
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cells with multi-lobulate or multiple nuclei, Fig. 1a and
1b. Vacuolation occurred in a substantial fraction of all
HUC-TC cultures (Fig. 1a) as would be expected during
infection with SV40. HUC-TC showed an increased ten-
dency to form foci and grew in vertical layers vs. their
non-transformed counterparts. Fig. 2 shows the growth
rate of HUC vs. HUC-TC in culture under identical
conditions, where it is apparent that HUC-TC possessed
a significant growth advantage.
MTS Assay for Cell Viability
In order to determine whether exposure of cells to IFN-
g produced cytotoxicity or reduced the cellular
metabolic rate, we measured cell viability using the
MTS assay after exposure to 830 ng/mL (100× [I]) of
IFN-g. From day 4 in the treatment regimen, IFN-g sup-
pressed cellular metabolism in a dose-dependent fashion
in both cell types (Fig. 3a, b). HUC-TC growth in the
presence of IFN-g was significantly inhibited (p < 0.05,
two-tailed paired t-test), however growth in HUC was
not significantly inhibited using the same criteria.
ELISA Assay for Interferon’s a and g
To explore whether the observed up-regulation of IFN-
related gene expression changes (see below) could be
explained, at least in part, by an increase in the secreted
IFN’s, levels of secreted proteins were measured. The
Figure 1 Morphology of parent, non-transformed a) HUC and transformed, tumorigenic b) HUC-TC. Note that HUC-TC are much larger
than HUC (both a & b are same magnification) and contain giant, multinucleated cells. H & E, magnification: 20×. Bar = 50 μm.
Figure 2 Growth rate of HUC-TC cells was significantly higher than HUC. (Error bars = SEM, average of 24 SD’s from n = 3 experiments).
Significance level = p < 0.05) for days 1-5 using two-tailed paired t-test.
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that of controls in HUC and HUC-TC cell culture
supernatants (data not shown). The SD between plates
or wells was < 0.01. In the IFN-a assay, there was < 50
pg/mL (data not shown) (experimental dish to dish
SD = 0.06, experimental well-to-well SD = 0.08) which
was similar to controls.
In vitro IFN-g Treatment of Cells
In order to determine whether exogenously-supplied
IFN-g would be stimulative or suppressive of growth in
transformed and non-transformed HUC if the production
had been increased by transformation, we measured
growth after exposing HUC and HUC-TC to inhibitory
([I]= 8.3 ng/mL) or 100× inhibitory (100× [I]= 830 ng/mL)
for seven days in culture. The results of IFN-g treatment
of HUC and HUC-TC cells in vitro for 7 days are shown
in Fig. 4. IFN-g suppressed growth significantly (p < 0.05)
only in tumor (HUC-TC) cells (triangles, dashed lines)
from days four through seven. HUC treated with IFN-g
(squares, solid lines) did not show significant growth
suppression.
Gene Expression Changes
In order to better understand the cellular changes
induced by transformation, differential gene expression
was examined in HUC-TC compared to HUC using the
Atlas
TM Human Cancer 1.2 Array (Cat. #7851-1). Table
S1 (Additional File 1) shows the fold change in gene
expression for selected gene families, with up- and
down-regulation. The most clear and numerous changes
represented virally related or responsive genes, many of
Figure 3 IFN-g suppressed metabolism in a) HUC or b) HUC-TC from days 4-7 in vitro. Treated (100× [I], 830 ng/mL) and control differed
significantly as measured by two-tailed paired t-test for HUC-TC but not HUC. Treatment with 1×[I] concentration yielded similar results (data
not shown). Error bars are ± 1 SD (n = 8).
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were significant (p < 0.05). The changes below relate to
changes in HUC-TC (= treated) vs. HUC (= control):
Effect of Tag on Cells (Pro-viral response)
The observed responses of HUC-TC vs. HUC that were
virally-related were surprising because HUC were also
SV40-exposed. Based upon extensive reviews of the
function of Tag in viral infection, expected pro-viral
responses include blocking antiviral responses, such as
apoptosis [10-14,25,26]. See table S1 (Additional File 1)
and Fig. 5 show up regulation of TRICK2A, IAP3,
HSIAH2, IRRP + DAP1 and TRAIL3,w h i c hm a yi n h i b i t
apoptosis directly or act as decoy molecules, binding to
and inactivating effectors of apoptosis. Several pro-apop-
totic caspases were also up regulated, in conflict with
the anti-apoptotic expression changes. Tag blocks apop-
tosis by binding and inactivating p53. The Sp1 transcrip-
tion factor was up regulated 1.9-fold, and it is known
that Tag recruits Sp1 in order to initiate transcription of
itself and other Tag-related mRNA’s, possibly by use of
its DNAJ-like molecular chaperone activity. Secondly,
blocking occurs through interference with PKR (RNA-
dependent protein kinase, p68 kinase), which blocks the
transcription and translation of viral mRNA’sa n dp r o -
teins and is pro-apoptotic. We observed evidence of
two-fold up regulated PKR.T h i r d l y ,T a gb l o c k st h e
action of MxA and MxAB, which also block viral
mRNA transcription and protein translation. MxA and
MxAB were up regulated by 8.3 and 4.6 fold, respec-
tively, representing a response to the presence of SV40
or its components. The effects of Tag are summarized
in Fig. 5.
Effect of IFN-g On Cells (Anti-viral response)
Because the actions of IFN-g are central to the innate
immune response, and often occur after viral challenge,
changes in IFN-g-inducible genes were considered to be
significant to SV40 exposure, but since both cell lines
were SV40 exposed, this extensive response was puz-
zling. The IFN-g inducible or related genes with altered
expression are listed in the first section of Table S1;
Additional File 1. IFP 9-27, IFI 56, IFI 78, 1-8D + 1-8U
protein, 11.5 kDa protein, PKR,a n dIFN a/b receptor a
subunit were up regulated, among others. Down regu-
lated genes included the IFN-g receptor, which may have
been either a response to increased receptor binding,
the absence of ligand, or a SV40-associated thwarting of
cellular mechanisms. Since no increase in secreted IFN-
g was measured, the second or third possibilities are
more likely. One of the known effects of IFN-g is an
increase in the expression of MHC Class I proteins, and
here several class I MHC genes were up regulated
(MHC Class truncated HLA G lymphocyte antigen, HLA
DR antigen-associated invariant subunit, HLA Class I
histocompatibility antigen C4a subunit). The increase in
this class of proteins is significant because cytotoxic T
lymphocytes (CTLs) recognize peptide antigens in the
context of class I MHC molecules, and CTL-mediated
immunity is important in the defense against both can-
cers and viral infections [27].
Signal Transduction
Typically, during transformation cell signalling becomes
altered. Aspects of MAPK, Ras, Sonic Hedgehog and Jak-
Stat signaling were affected, some of which were explained
by known responses to viruses. The Jak-Stat response to
Figure 4 Exogenous IFN-g suppressed cell growth in HUC-TC (triangles and dashed lines), but not HUC (squares and solid lines) on
days 4-7. Error bars represent SEM as for Fig. 2. *p < 0.05, 2-tailed paired t-test.
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Page 5 of 14Figure 5 Tag binds to and inactivates many host proteins, especially p53 and pRB. Binding blocks pRB-mediated cell-cycle arrest and p53-
mediated apoptosis. When E2F is not bound by pRB, it dimerizes with DP1 and DP2, initiating transcription of cell-cycle progression genes. PKR
binds and is activated by the presence of double-stranded RNA, and activates pathways leading to apoptosis. Bound PKR activates NFB, causing
dissociation from IB. The transcription factor NFB binds cellular DNA and stimulates transcription of target genes resulting in either
proliferation or apoptosis. Phosphorylation of PKR is initiated by binding to ds RNA, and PKR then causes eIF2a, an initiator of transcription that
stimulates viral protein transcription/translation, to be released from its inactive state. Tag can also act on eIF2a causing downstream rescue of
translation of viral proteins. Tag recruits SP1, a transcription factor that, together with DNA primase and ligase, initiates more Tag transcription, as
well as of genes under the control of Tag. Tag also recruits RNase L-inactivator. The latter acts on ds viral RNA and converts it to inactive ss RNA,
and is pro-apoptotic. The active homodimer of endonuclease RNase L is activated by 2’-5’ OAS 1 & 2. See Table S1 (Additional File 1) and text
for genes altered in this study.
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observed in agreement with the literature. Jak-Stat activa-
tion occurs with the ATP phosphorylation of Stat-1, fol-
lowed by its translocation to the nucleus, where it may
dimerize with SP1 (up regulated here) and initiate the
transcription of NCAM1, or form a trimer with p48 and
Stat-2 (up regulated here) and initiate the transcription of
IFN-inducible genes (see above and Fig. 6). The down-reg-
ulation of the IL-6 precursor may represent a negative
feedback loop for Jak-Stat pathway de-activation.
Extracellular Matrix Reorganization
Because the ECM is typically degraded during cancerous
cell invasion, these changes may have been related to 3-
MC exposure. All ECM gene expression changes were
decreases (see Table S1, Additional File 1). The changes
within this group included collagens, cytokeratins, integ-
rins and glucocorticoid receptors which may be related
to the induction of metastasis. Several matrix metallo-
proteinases and N-gal (neutrophil gelatinase), which are
associated with tumor invasiveness, were up regulated.
Figure 6 How the presence of virus acts on innate immune system components, i.e. interferons, activating the Jak-Stat pathway.
Double-stranded RNA, the product of viral replication, is recognized by interferons a, b, and g and they in turn (especially a and b) activate PKR.
See Fig. 5 for PKR actions. Interferons also activate MXA and MXAB which block transcription of viral products by the viral polymerase, and
activate 2’-5’ OAS 1 & 2, which inhibit viral protein synthesis and stimulate apoptosis. However Tag may block the actions of 2’-5’O A S1&2b y
initiating transcription of inhibitors of apoptosis genes (see small orange sunburst block). Interferon a, EGF, and IL-6 activate Jak-Stat pathways,
activating Stat1 which becomes phosphorylated and binds p48 and Stat2 (the trimer is ISGF3 or STAT1), bind to the ISRE on DNA and initiate
transcription of IFN-inducible genes (one of which is IL-6, see large orange sunburst box). Stat1 also binds SP1 and this dimer initiates
transcription of NCAM1, a cell adhesion molecule. Genes colored in yellow-orange denote altered gene expression levels measured.
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DNA damage might have been caused by exposure to 3-
MC, and could have been defective, resulting in trans-
formation to carcinogenicity. Several DNA damage
response genes showed altered expression, most notably
GADD 153 (4.1 fold up regulated). XPG group E, XPG
DNA excision repair, DNA mismatch repair PMS1, DNA
recombination & repair protein HNGS1 were up regu-
lated (see Table S1, Additional File 1). Down regulated
genes included DNA Ligase IV, ERCC1 and XPD group
D. The gene expression results are summarized in Fig. 7
for pro- and anti-viral responses and their end results,
showing how these changes might be related to
transformation.
TaqMan™ Quantitative RT-PCR Confirmation of Selected
Gene Changes
Several genes were chosen to corroborate the gene
expression results obtained from the arrays. The genes
C D K 4 ,D P 2 ,p 1 6 ,b-actin, FRA1, GSH synthetase and
p21
waf1/cip1 were chosen based on relevance to the
mechanisms of action of SV40 (and in the case of GSH
synthetase, 3-MC) and strong response on the gene
expression array. Fig. 8 shows the relative fold-change in
expression using the Taqman™ assay (n = 5), where all
changes except p16 were significant at the level of p <
0.05, and the Clontech™ gene expression array, where all
changes measured were significant at p < 0.05. The
intra-sample variance was 0.05, 0.06 and 0.10 for cdk4,
dp2 and p16ink4, respectively, e.g., and the maximum
fold change was 1.5. Close agreement was achieved
between the two methods.
Discussion
The morphology, growth characteristics, phenotype, kar-
yotype, and ultrastructure of these cell lines were exten-
sively described previously [24,28-35]. The parent HUC
non-transformed cell line did not produce tumors after
inoculation in vivo up through at least passage 80 (over
3 years) in culture. However, the parent cell line was
highly unstable chromosomally. Wu et al. [33] demon-
strated that marker chromosomes of 3 tumor cell lines
(HUC-TC) were stabilized relative to the parent non-
transformed cell line, by malignant transformation.
HUC-TC were transformed at passages 12-15, and we
obtained cells from the repository that were passage 14.
We used these cells at passage 19. We obtained the par-
ent HUC non-transformed cell line at passage 32 and
used it at passage 38. We inoculated these HUC-TC
(passage 19) into athymic mice and tumors were pro-
duced in the same manner as the original experiments
[24], (data not shown). Given the previous extensive
characterization of these cells and the limited number of
passages that elapsed between the time we obtained and
used the cells for experimentation, the likelihood of sig-
nificant alterations in the genome is limited, but cannot
be completely ruled out.
It was expected that the gene expression results would
strongly reflect the 3-MC treatment. We chose to use
the human cancer array and therefore changes in other
metabolic genes such as CYP1A1, which is also known
to occur upon 3-MC treatment, were not measured.
The gene expression changes seen upon comparing
HUC with HUC-TC were surprising in that they were
highly related to SV40 treatment although both cell
types had been SV40-treated. It appeared that a non-
transient (i.e., present through several cell passages)
expression and enhancement of anti-viral responses
occurred in HUC-TC as a result of the treatment with
3-MC. Below we discuss how this activity might result
in carcinogenesis.
Cellular antiviral responses typically begin with host
cell recognition of the internal presence of SV40 dou-
ble-stranded RNA, an indicator of viral replication [25].
The response includes up-regulation of IFN’s a/b/g,
with multiple effects such as up regulation of the
expression of 2’,5’-OAS 1 and 2, seen here, activating
the RNase L homodimer. Active RNase L then cleaves
double-stranded viral RNA and stimulates apoptosis.
But clearly apoptosis was not activated (Fig. 1, which is
a representative image, shows no apoptotic cells or
bodies and Fig. 2 shows that both cell types had a
healthy growth rate in culture). The activation of PKR
by type I interferons would then typically result in bind-
ing of eIF2a to GDP and eIF2b, a recycling factor for
eIF2a, inactivating eIF2a and blocking the initiation of
protein translation. (The down-regulation of the related
eIF4E 25-kDa subunit, in this experiment, may have
been another mechanism of decreased protein transla-
tion.) PKR then typically activates NFB, which translo-
cates to the nucleus, binds DNA in the promoter
regions of NFB-responsive genes, and initiates tran-
scription of proliferation-related or stress-responsive
genes, the latter of which lead to apoptosis. PKR activa-
tion blocks viral transcription and translation, as does
the up regulation of MxA and MxAB (up regulated
here) in response to interferons. Here, PKR may have
stimulated pro-proliferative genes but pro-apoptotic
genes may have been incompletely or improperly acti-
vated, or such activation may have been ineffective due
to the up regulation of opposing signals (see below).
Waring, et al. [20] have identified a gene expression
profile that is similar to that of 3-MC and mediates
hepatic toxicity through the AhR either directly or
through the effects on NFB, resulting in the inhibition
of cell adhesion protein expression. If such a pathway
acts through NFB, it may be similar to the PKR-
mediated NFB activation pattern seen here, producing
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Page 8 of 14Figure 7 3-MC treatment of SV40-immortalized cells induced pro- (mediated by Tag) and anti- (mediated by innate immune system)
viral responses, extracellular matrix reorganization, antigen presentation, recruitment of B- and T-cells, activation of MAPK, JAK/STAT,
ras, etc. signal pathways, blockage of apoptotic response, and stimulation of proliferation (through blockage of cell cycle arrest), together with
activation of oncogenes and inactivation of tumor suppressor genes (tsg’s), as well as a DNA damage response (with possibly defective repair).
This resulted in a shift of the balance of birth and death toward proliferation, development of a tumorigenic/metastatic phenotype, and
sometimes, the vacuoles typical of SV40 viral infection.
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ments were up regulated (endonuclease III, caspase 4,
caspase 10, death receptor 5 (TRICK2A), TNFRSF25
( W S L+T R A M P+A p o - 3+D D R 3 ) ) however these cells
were not apoptotic. The reason for unchecked prolifera-
tion may be related to the up regulation of multiple
blockers of apoptosis (DR1, HSIAH2, IAP3, DAP1),
known to act either as decoys that bind and inactivate
apoptotic ligands, or act upstream of the caspases. In
addition, pRB is known to be bound by Tag, nullifying
cell cycle checkpoint control. p53 protein was at least
partly functional in these cells, as we noted several p53-
inducible gene expression increases, as well as mdm2 up
regulation. However Tag is known to bind p53 and ren-
der it incapable of initiating apoptosis. Although p53
and pRB binding by Tag can account for both loss of
apoptosis signaling and checkpoint control, there were
many other changes at the mRNA level related to these
important functions and indicative of cellular
dysregulation.
Cell-cycle arrest was signaled as well, since p21
waf1/cip1
(up regulated) is a p53-inducible universal CDK inhibi-
tor and its up regulation is known to inhibit cell prolif-
eration. The response was clearly not successful, most
likely due to pRB-Tag binding. Tag was present in these
cell lines [32], and there was evidence of an increase in
the rate of proliferation in HUC-TC vs. HUC. Other
cell-cycle genes up regulated include CDK4/cyclin D2
and CDK7. CDK7 together with cyclin H forms CAK,
a kinase required for CDK activation. Although p16
ink4
was up regulated, it could not bind pRB, which
would have been already bound by Tag, and so
could not block cell cycle progression. Ultimately,
apoptosis was blocked and cell-cycle control circum-
vented (Fig. 5, 6, 7).
These results imply stimulation of IFN-g-related path-
ways by 3-MC. Treatment with exogenous IFN-g
blocked cell proliferation in tumor, but not non-tumor
HUC. However metabolic activity (as assayed by MTS)
was decreased in both cell lines treated with IFN-g from
day 4 onward. Since there was no elevation in the level
of secreted IFN a or g,a n dm a n yI F N - g-inducible tran-
scripts were increased, we conclude that 3-MC treat-
ment activated IFN pathways without affecting
constitutive levels of IFN. An hypothesis is that activa-
tion of IFN-g-related pathways by 3-MC rendered HUC-
TC susceptible to growth-suppression by exogenous
IFN-g. These data support the idea that during immor-
talization (first step, SV40-mediated) cells become unre-
sponsive to IFNg-mechanisms of cell cycle control, but
subsequently, during transformation (second step, 3-
MC-mediated) cells are altered in such a way that they
are rendered sensitive to IFNg control of cell prolifera-
tion, but by then it is too late because other aspects of
cellular function controlling growth have been irrevoc-
ably altered. The cell cannot ‘retreat’ along the pathway
Figure 8 Comparison of RT-PCR and array data showing good agreement between methods for 7 selected genes (b-actin =
endogenous control) in HUC-TC vs. HUC cells (*significantly different than HUC at p < 0.05). Error bars = SEM.
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immortality. The ‘coup de grace’, 3-MC transformation
of the primed cell population, might then be facile.
Clearly the IFN-g pathways activated by 3-MC were not
intrinsically growth-suppressive in nature, since HUC-TC
exhibited more rapid growth than HUC in the absence of
treatment with exogenous IFN-g. Activation of IFN-g-
inducible gene expression may represent dysregulation of
homeostatic IFN-g pathways. This raises the question of
how the altered pathways promote tumor growth and
metastasis. We would remind the reader that it is known
that a slight deviation in one or more components of a
growth-suppressive pathway may alter the function of the
entire pathway, achieving the opposite effect, e.g. TGFb
signalling either promoting or suppressing tumors [36].
Demonstration of the suppressive effects of IFN-g on
cancer cell growth both in vitro and in vivo has been
unequivocal [37-39] and the production of IFN-g in
response to chemotherapy is one marker used to assess
the success or failure of treatment in vivo; it is considered
an indicator of immune activation and anti-tumor activity
[40,41]. In addition, studies of infectious diseases (scrapie,
herpes simplex virus type 1, human cytomegalovirus,
human influenza virus C, type 1 diabetes) have linked
IFN-g inducible gene expression with the presence of dis-
ease and/or anti-viral mechanisms [42-45]. In a recent
study employing HTLV-1 to transform Rat-1 fibroblast
cells in vitro, four of eight up regulated genes were IFN-
stimulated genes, and the 2’,5’-OAS promoter was acti-
vated by viral Tax indirectly through an NFB-dependent
pathway, linking IFN-signaling with Tax transformation
[46]. We observed evidence of PKR up-regulation, which
can directly activate the NF-B pathway. The present
study may be another example of transformation that
occurs via IFN-g pathways.
The most highly up regulated gene was lipocalin (neu-
trophil gelatinase-associated lipocalin, NGAL). Lipocalin
has been found in a high molecular weight complex
associated with progelatinase B, one of several gelatinase
isoforms commonly found in the urine and cancerous
tissues of bladder cancer patients [47]. Since 3-MC is a
known human uroepithelial carcinogen which has pre-
viously tested positive for tumorigenicity in mice in vivo
[48], this transcriptional up regulation appears to be a
correlate for urothelial malignancy, and makes lipocalin
a biomarker of exposure as others have observed for
bladder cancer [49], as well as colorectal cancer [50],
and as reviewed in [51].
These data provide evidence that SV40 and 3-MC may
act synergistically to promote transformation to a
tumorigenic phenotype. Inoculated HUC-TC produced
tumors in athymic mice as in the original experiments
and we found gene expression changes related to viral
elements to be up regulated, along with many
interferon-responsive genes. We hypothesize that first
SV40 infection altered cellular pathways related to cell
cycle control and apoptosis, then 3-MC exposure
initiated changes in interferon response elements, matrix
attachment proteins, DNA damage responses, and acti-
vation of oncogenes and/or inactivation of tsg’s, result-
ing in transformation to the malignant phenotype. This
may be relevant to human environmental exposures.
Methods
Cell Culture, Morphology and Histologic Staining
HUC and HUC-TC were obtained from The American
Type Culture Collection, Rockville, MD at passage 32
(HUC) and 14 (HUC-TC). HUC (passage 38) and HUC-
TC (passage 19) cells were plated onto 150 mm dishes
(five per treatment) at a density of 1 × 10
5 cells/mL and
allowed to reach 80 - 90% confluence, or 5 days, under
standard culture conditions. Cells were fed three times
per week (26 mL/dish MEM containing 10% FBS,
0.1 mM non-essential amino acids, 2 mM L-glutamine,
2.7 mg/mL D-glucose, 10 μg/mL insulin, 5 μg/mL trans-
ferrin, 0.1 μg/mL hydrocortisone). Glass coverslips were
placed into the 150 mm dishes at the time of plating
and carefully removed with forceps before RNA harvest
was carried out on the remaining cells. Cells from glass
coverslips were fixed by rinsing in room temperature
sterile PBS and fixed in cold (-20°C) absolute ethanol
for 24 h, stained using Hematoxylin and Eosin by stan-
dard histologic staining methods, and photographed.
MTS Assay for Cell Viability
The Promega Cell Titer 96 Aqueous One Solution™
assay was employed to measure the metabolic activity of
IFN-g-treated HUC and HUC-TC cells relative to con-
trol cells. This assay relies on the conversion of a tetra-
zolium compound (MTS) to a blue colored reduced
formazan product, which requires cellular reducing
capacity as NADH and NADPH. Cells that are not
metabolically competent will not reduce MTS. Cells
(HUC = passage 37, HUC-TC = passage 18) were plated
at a density of 1.25 × 10
4 cells/mL into 96-well plates
(Corning plastic, one plate/cell type/day for a total of 12
plates) and grown for 7 days. Cells were fed with fresh
media, 1× [I] (where [I] = 8.3 ng/mL) or 100× [I], IFN-g
on days 2, 4 and 6. On days 2 - 7 one plate of each cell
type was assayed using the MTS reagent. 20 μLo fM T S
reagent was added to each well and plates were incu-
bated in the dark under standard tissue culture condi-
tions for one hour. Optical density was measured on a
Titertek Multiskan™ spectrophotometer at 490 nm. 8
wells were read per treatment condition, on each plate,
and the readings averaged. Statistical analysis was car-
ried out using an Excel™ spreadsheet and significance
levels analyzed using a paired two-tailed t-test.
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Assays for quantitation of secreted interferons a and g
were performed in a 96-well format using commercially
obtained assay kits. A Quantikine (DIF50, R & D Sys-
tems, Mpls., MN) kit was used for human IFN-g
including calibrated pure recombinant human inter-
feron standards and a polyclonal antibody specific for
human IFN-g. A similar IFN-a kit was obtained from
PBL Biomedical Laboratories, Inc. (product #41400,
v.2.2). Standard curves for each were constructed and
interferons were quantitated in pg/mL, according to
manufacturers’ instructions. HUC-TC cells (passage 38
or 39 for IFN-a or IFN-g r e s p e c t i v e l y )w e r ep l a t e da ta
d e n s i t yo f1 . 2 5×1 0
4 cells per mL into six dishes per
cell type, and 100 μL of purified cellular supernatant
per well was pipetted into the antibody-coated 96-well
plate. The assay was carried out per the manufacturer’s
instructions, and results were read spectrophotometri-
cally. Statistical analysis was carried out using an
Excel™ spreadsheet.
In vitro IFN-g Treatment of Cells
To assess the effect of IFN-g on cell growth in culture,
HUC (passage 40) and HUC-TC (passage 21) were trea-
ted with a known inhibitory concentration [I] of 8.3 ng/
mL recombinant human IFN-g (specific activity 2 × 10
8
U/mg, #I-3265, Sigma Chemical, St. Louis, MO) or con-
trol media 1 day post-plating, and grown for six days
without media replacement. On day zero, cells were pla-
ted into 24 each 25 cm
2 flasks at a density of 1.25 × 10
4
cells/mL (six control and six treated for HUC and HUC-
TC). One dish from each treated and control dish was
trypsinized using standard methods and counted each
day beginning on day two post-plating. Counts were
taken using a standard hemacytometer, in duplicate, and
the results averaged. Significance was determined using
an Excel™ spreadsheet and a paired two-tailed t-test.
RNA Preparation and Labeling of cDNA and Hybridization
to Arrays
RNA was extracted by the addition of 14 mL TRIZOL™
reagent (Gibco BRL, Grand Island, NY) after triple rin-
sing with sterile room temperature PBS, according to
the manufacturer’sp r o t o c o l .S i xμgo ft o t a lR N Ap e r
sample was reverse-transcribed and radioactively labeled
using a
33P-dCTP in a previously-described PCR reaction
[52]. Labeled cDNA was hybridized overnight at 64°C
and washed free of unhybridized cDNA in 0.5× SSC/1%
SDS once, then twice in 2× SSC/1% SDS (20 min. per
w a s h )a t6 4 ° C .M e m b r a n e s( A t l a s ™ Human Cancer 1.2
Array [Cat. #7851-1], n = 5 per treatment) were exposed
for 48 h to a rare-earth screen and read on a phosphori-
mager (Cyclone™ Scanner).
Data Manipulation & Statistical Analysis
The resulting intensities were uploaded into the Atlas
Image 1.5™ software program (Clontech Inc., Palo Alto
CA). Membranes were then aligned according to the
manufacturer’s instructions using the global normaliza-
tion option and screened for bleed or other anomalies.
The resulting reports were analyzed by group, for statis-
tical significance (p < 0.05), using the NoSeCoLoR
(NLR) software program, a normalization and local
regression program [53] as in previous studies [52]. Sta-
tistically significant results were interpreted by use of
current literature and diagrams constructed integrating
experimental results with known biological pathways.
TaqMan™ Quantitative RT-PCR Confirmation of Selected
Gene Changes
Using RNA from the same experiment as for gene
expression, the expression changes of selected strong
responding genes were confirmed using a Taqman™ real
time quantitative RT-PCR assay (Perkin Elmer Prism
ABI), as previously published [52]. Primers were
designed using Perkin Elmer Primer Express™, purchased
from Keystone Biosource Inc. (Camarillo, CA) and pre-
pared according to the manufacturer’s instructions. The
genes chosen for this assay were: CDK4, DP2, p16
ink4, b-
actin (endogenous control), FRA-1, GSH synthetase and
p21
waf1/cip1. These genes were altered on the array at p
< 0.05, and were relevant to the mechanism of action, as
observed by array results. The ΔΔCT method was used
to calculate the fold-change in gene expression for the
selected genes. b- a c t i nw a su s e da st h ee n d o g e n o u s
control.
Additional file 1: Table S1 - Gene Expression Changes in 3-
methylcholanthrene transformed HUC (p < 0.05).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-2867-10-4-
S1.PDF]
List of abbreviations
3-MC: 3-methylcholanthrene; SV40: Simian virus 40; HUC: human
uroepithelial cells; HUC-TC-human uroepithelial cells (tumor cells); IFP 9-27
‘protein 9-27’: interferon-inducible protein 9-27; IF 56: interferon-inducible 56
kDa protein; MxA: interferon-regulated resistance GTP-binding protein (IFI-
78K); MxAB: interferon-regulated resistance GTP-binding protein; IFN-ga , b:
interferon gamma; alpha; beta; Tag: Large T antigen of SV40; tag: small t
antigen of SV40; p53: tumor suppressor protein p53; pRB: retinoblastoma
protein; CBP: CREB binding protein; transcriptional co-activator for IRF genes;
p300: as a dimer binding to CBP; forms a transcriptional co-activator for IRF
genes; Ah receptor: aryl hydrocarbon receptor; ARNT: Ah receptor nuclear
translocator; XRE: xenobiotic response element; ARE: antioxidant response
element; CYP1A1: cytochrome p450 1A1; AP-1: jun/fos dimer; activator of
transcription; a
33P-dCTP: the a-labeled; phosphorus 33 radioisomer of
deoxycytidine triphosphate; CDK4: cyclin-dependent kinase 4; DP1 and 2:
dimerization partner 1 and 2; p16
ink4: tumor suppressor protein p16 mRNA;
b-actin: “housekeeping” gene; cytoskeletal-associated; Fra-1: fos-related
antigen 1; GSH synthetase: glutathione synthetase; p21
waf1/cip1: universal
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Page 12 of 14cyclin-dependent kinase inhibitor; TRICK2A: death receptor 5 or DR5 (also
Apo2; TRAIL-R2; TRICK2; or KILLER); IAP3: inhibitor of apoptosis protein 3;
HSIAH2: inhibitor of apoptosis protein 2; IRRP + DAP1: death-associated
protein + death-associated protein 1; TRAIL3: TNF-related apoptosis-inducing
ligand 3; Sp1: transcription factor; PKR: RNA-dependent protein kinase; p68
kinase; DNA-J: a molecular chaperone; 1-8D + 1-8U protein: interferon
inducible protein mRNA; MHC: major histocompatibility complex; HLA:
human lymphocyte-associated; DR: decoy receptor; NCAM1: neural cell
adhesion molecule 1; JAK-STAT: Janus kinase and signal transducer and
activator of transcription; p48: damage specific DNA binding protein subunit
mRNA; IL-6: interleukin 6 mRNA; ECM: extracellular membrane; GADD 153:
growth and DNA damage protein 153; XPG: xeroderma pigmentosum;
PMS1: mismatch repair gene; HNGS1: DNA recombination and repair protein
mRNA; ERCC1: DNA excision repair gene; 2’,5’-OAS: 2’,5’ oligoadenylate
synthetase; eIF2a: eukaryotic translation initiation factor 2 alpha; GDP:
guanidine diphosphate; NFB: nuclear factor kappa B; mdm2: feedback
regulator of p53 (an ubiquitin ligase); CAK: cyclin-associated kinase (activator
of CDK’s); NGAL: lipocalin (neutrophil gelatinase-associated lipocalin
precursor); E2F: transcription factor; ICE: interleukin-converting enzyme, ISRE:
interferon-stimulated response element; ISGF3: STAT1; tsg’s: tumor
suppressor genes; tl’n: translation; tx: transcription; WSL+TRAMP+Apo-3
+DDR3: TNFRSF 25 (TNFRSF12).
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